Pregnancy and Addiction 1

Size: px
Start display at page:

Download "Pregnancy and Addiction 1"

Transcription

1 Disclaimers Addiction and Pregnancy 2017 Carl Christensen, MD, PhD, D-FASAM Clinical Assoc Prof, Psychiatry and OB/Gyn, Wayne State Univ School of Med, Detroit Mi Medical Director, Mich Health Professional Recovery Program June 15, 2017 No Financial Relationships Consultant, DEA/DOJ Consultant, BCBS Mich Methadone provider, Wayne State SOM Medical Director, Dawn Farm, Ann Arbor, MI Buprenorphine and naltrexone provider, A2 3 Qualifications: Carl Christensen Disclosures II Medications will be referred to in the generic whenever possible; will discuss FDA specific formulations We will be discussing off label use of buprenorphine and methadone; neither of these are approved by the FDA for use of opioid dependence in pregnancy WHY TALK ABOUT THIS? WHY TALK ABOUT THIS? Addiction and Pregnancy 11 Addiction and Pregnancy 12 Pregnancy and Addiction 1

2 WHY TALK ABOUT THIS? WHY TALK ABOUT THIS? NAS in Michigan You are here.. HEROIN Addiction and Pregnancy 13 Addiction and Pregnancy 16 NAS OPIOID USE rural Urban JAMA Pediatrics December 12, 2016 Online What is Addiction? 20 What is Addiction? Physiologic Dependence? Lack of willpower? An amoral condition? A brain disease? Pregnancy and Addiction 2

3 21 Physiologic Dependence: Tolerance and Withdrawal Tolerance: requiring increasing amounts of drug to get the same effect Withdrawal: the opposite effect of the drug when it is removed NEITHER of these imply chemical dependency (addiction) Lack of Willpower? 22 An amoral condition? Brain disease? 25 The Nucleus Accumbens: the Pleasure Center. Dopamine: the Pleasure DRUG 26 VTA: the gas tank : supplies dopamine to the Nucleus Accumbens Pregnancy and Addiction 3

4 Frontal Cortex: inhibits the What is the problem? Pleasure Center (maybe) Addiction is not a problem of drug WITHDRAWAL What is the problem? Drug WITHDRAWAL: the Hindbrain Addiction is not a problem of drug WITHDRAWAL.. It is a problem of: CRAVING LOSS OF CONTROL COMPULSIVE USE USE DESPITE CONSEQUENCES (the 4 Cs ) 31 Drug ADDICTION: the (primitive) Forebrain: 33 Pregnancy and Addiction 4

5 39 Why Can t Addicts Stop????? The relapse rate after undergoing detox approaches 100% The relapse rate when coming off meds (buprenorphine, methadone) is 90% But: their withdrawal is gone. SO: why do they relapse????? 40 Normal Volunteers Red: good blood flow Non users Cocaine users, 10 days sober Cocaine Users, 100 days sober High blood flow Low blood flow [C-11]d-threo-methylphenidate How Long to recover from Methamphetamine? Normal Control Methamphetamine Abuser (1 month abstinent) high low Treatment of Opioid Dependence (without) Pregnancy Methamphetamine Abuser (14 months abstinent) Volkow et al., J. Neuroscience, Medication Assisted Therapy (MAT): Agonists vs. Antagonists Drug Type Analogy Methadone Full Agonist High Octane Buprenorphine* Partial Low Octane Agonist Naltrexone Antagonist Water Medication Assisted Therapy (MAT): Methadone Pregnancy and Addiction 5

6 Medication Assisted Therapy (MAT buprenorphine Medication Assisted Therapy (MAT naltrexone BOTTOM LINE: (non-pregnant) In both controlled and retrospective studies, the success rate for most medications is between 40 and 60% (one to two years). When patients come off the medication, they relapse. Relapse may be associated with an increased chance of overdose and death. Benefits of Methadone Salsitz, ASAM, 2012 Reduction in death rates (Grondblah, 1990) Reduction in IVDU (Ball & Ross, 1991) Reduction in # of crime days (Ball & Ross) Reduced HIV seroconversion / HCV conversion IMPROVED OUTCOME AFTER INCARCERATION 59 Ball 1988: reduction in IVDU Ball 1988: reduction in IVDU ORT: yes or no??? 61 ORT: yes or no??? 62 Pregnancy and Addiction 6

7 Ball 1988: resumption of IVDU! Ball 1988: resumption of IVDU! ORT: yes or no??? 63 ORT: yes or no??? 64 Problems with methadone Buprenorphine Requires initial daily dosing first 90 days. Must be clean for 2 years before you can increase take homes! Methadone clinics may be a source of wet faces and wet places Stigma Judges will often try and force moms off methadonenow forbidden by the feds. A partial opiate agonist (less potent) Less analgesic effect Less respiratory depression <100 documented deaths in the U.S. (Soyka); PER YEAR WITH METHADONE Treats both pain and opiate dependency Different formulations are approved Addiction and Pregnancy 66 Buprenorphine +/-Naloxone: Buprenorphine: Available in 3 branded forms: Generic buprenorphine (Subutex ): sublingual OFF MARKET: Medicaid may not cover generic due to concerns about diversion. Bunavail : sublingual buprenorphine + naloxone (Narcan ): prevents IV use* Suboxone : sublingual buprenorphine + naloxone (Narcan ): prevents IV use* Zubsolv : ditto Formulations approved for PAIN: Buprenex : parenteral, used in the hospital setting. Butrans : weekly patch, 10 to 20 mcg/hr Belbuca : buccal film from mcg/24 hr. ANY of these will precipitate sudden withdrawal: only give when patient is going INTO withdrawal! Addiction and Pregnancy 67 * not FDA approved for pain Addiction and Pregnancy 68 Pregnancy and Addiction 7

8 What Formulation Should You Use? Buprenorphine long-term follow up: Fiellin, 2008 Generic buprenorphine avoids naloxone. It is more susceptible to diversion Use whatever their insurance will pay for!! 69 Concerns about buprenorphine It can be abused (mostly for withdrawal) It is unsafe when combined with sedatives & alcohol. It is an opioid. Relapse rates after detox exceed 90%. (Weiss, 2011) Vivitrol (injectable naltrexone) for opioid dependence This medication is not currently used during pregnancy; but may be used following delivery. 71 Addiction Tx in Russia Vivitrol: abstinence (50%) Kupitsky et al; Lancet 2011; 377: C / Pregnancy and Addiction 8

9 No Vivitrol, Control Treatment (40%) No Vivitrol; No Treatment (0%) Due to Vivitrol (naltrexone) Due to treatment Why the handcuffs? Vivitrol: craving CONTROL VIVITROL Vivitrol: craving Vivitrol: concerns CONTROL VIVITROL As with methadone and buprenorphine, when the medication is stopped, relapse may lead to death due to lack of tolerance. It would be very difficult to treat acute pain while on Vivitrol : suggestion is 20x normal dose. Ex: a patient underwent emergency operative laparoscopy 2 weeks after Vivitrol injection. He was treated with IV Dilaudid, 10 to 20 mg/hr. Pregnancy and Addiction 9

10 Luty 2003 Doc, when can I get off this sh*t medication? Can you detox off MAT? 101 women underwent detox during pregnancy 40 successfully detoxed. No adverse fetal effects documented BUT: Luty et al, J Sub Abuse Treat 24 (2003); ORT: yes or no??? 83 Maintenance vs. Detox? Kakko et al heroin addicts were started on buprenorphine/naloxone. 20 were detoxed off and offered counseling. 20 were kept on buprenorphine/naloxone and offered counseling. A year later. ORT: yes or no??? ORT: yes or no??? Can you taper off buprenorphine without relapse? 87 ORT: yes or no??? Pregnancy and Addiction 10

11 Buprenorphine in opioid dependence 654 patients enroll on buprenorphine for 2 weeks. 50% stay abstinent. They are tapered off and over 90% relapse. 360 remain, they go back on buprenorphine for 12 weeks, 50% stay abstinent. They taper off and 90+% relapse. Moral of the story: medications work as long as you take them. Your Baby Will Die If You Detox : Opioid Detox During Pregnancy Fetal death during pregnancy is rare. Patients can be successfully and safely detoxed. The lowest neonatal abstinence rates are seen with incarcerated patients (19%). Bell et al, AJOG 2016; 215: 374.e1-6 What is the Risk of Dying in and out of Treatment? Relative Risk= the risk of dying compared to someone who does NOT have opioid addiction RR= 1 without addiction. If RR >1 you are more likely to die. Mortality and M.A.T (bup and MTD) 122, 885 patients: OD mortality NO ADDICTION: RELATIVE RISK IS ONE (1) METHADONE BURPENORPHINE In treatment Out of treatment In Treatment Out of Treatment Sordo L et al. Mortality Risk during and after opioid substitution treatment: systematic review and meta0analysis of cohort studies. BMJ 2017; 357: J1550 Take Home Points: Mortality appears to decrease (29%) after starting medication assisted treatment. Mortality INCREASES after leaving treatment. Both the first two weeks IN treatment (methadone ) and OUT of treatment (methadone and buprenorphine) are the most dangerous periods. Treatment of Opioid Dependence During Pregnancy Pregnancy and Addiction 11

12 101 METHADONE the gold standard Was only approved for use for addiction in 1965; Dr. James Wardell started in Detroit in TIP 40: methadone is (was) the preferred treatment in pregnancy Buprenorphine was considered experimental. Improvement in neonatal outcomes documented by Ed Johnson and Andre Jones. Maternal Opioid Treatment: Human Experimental Research (MOTHER) MOTHER STUDY :NEJM 2010; 363: Addiction and Pregnancy 103 Double blinded, RCT Methadone vs. buprenorphine Contingency management (financial incentives $$$$) CBT (cognitive behavioral tx) Transportation, etc. NO polysubstance dependence x tobacco! Addiction and Pregnancy 104 MOTHER STUDY Sites Patients already on methadone are admitted to research unit for detox 6 mg MS/mg methadone (4 divided doses) Rescue doses prn Kept until stabilized THIS IS NOT FEASIBLE IN CLINICAL PRACTICE!!!!!!!!! Randomized to study meds on L & D Johns Hopkins, Baltimore MD T. Jefferson Univ., Philadelphia, PA Women & Infants, Providence RI Vanderbilt UMC, Nashville, TN St. Josephʼs Hlth Ctr. Toronto, Canada Wayne State Univ., Detroit, Michigan University of VT, Burlington, VT Addiction Clinic Vienna, Austria Addiction and Pregnancy 105 Addiction and Pregnancy 106 Pregnancy and Addiction 12

13 Methadone vs. Buprenorphine: the MOTHER study Measure Methadone Buprenorphine Amount of MS required # of days in hospital Duration of treatment for NAS Birthweight % preterm delivery 19 7* Positive drug screen at delivery 15% 9%* Dropped out 18% 33 MOTHER study. Buprenorphine exposed neonates exhibited fewer stress-abstinence signs, were less excitable less hypertonia better selfregulation and required less handling than methadone-exposed neonates. Jones Finnegan & Kaltenbach Drugs 2012 Addiction and Pregnancy Who should NOT go on buprenorphine? Patients who are: Already on methadone (>35 mg) Active hepatitis C (high LFTs) Unable to engage in treatment Taking benzos Plan on mixing bup with their opiates Are diverting Can t get insurance coverage Buprenorphine-->Methadone? NOT necessary! Can continue buprenorphine Risk of NAS is decreased (severity and duration)with buprenorphine as compared to methadone! Again, neither of these is APPROVED for treatment of opioid dependence during pregnancy. Addiction and Pregnancy 116 Addiction and Pregnancy 118 Methadone à Buprenorphine? Methadone: Has a LONG half life MOTHER study dropouts were partially due to attempts to convert high dose methadone to buprenorphine Current expert opinion is to limit to patients on mg. Safest course may be to remain on methadone. Addiction and Pregnancy 119 Current Management: Eleonore Hutzel Recovery Center/ Tolan Clinic, Detroit Mich Patients who present on SHORT acting opioids: buprenorphine Patients who present on long acting opioids or methadone: methadone Benzodiazepine use must stop immediately or they will be referred for methadone. 120 Pregnancy and Addiction 13

14 Management of Labor/Postpartum in the Recovering Patient Labor may be a trigger for relapse Epidurals should be encouraged Donʼt discharge patients with short acting opiates whenever possible! For C/S patients: need to involve family, social work, addictionist when dispensing opiates RESIDENTS: Confirm EVERYTHING the patient tells you!! 136 Who is Behind the Opioid Epidemic? Addiction and Pregnancy 135 Unintentional overdose deaths involving opioid analgesics parallel per capita sales of opioid analgesics in morphine equivalents by year, U.S., Rates of Opioid Sales, OD Deaths, and Treatment, Opioid Sales KG/10,000 Opioid Deaths/100,000 * Number of Opioid sales 600 Deaths (mg/person) '97 '98 '99 '00 '01 '02 '03 '04 '05 '06 '07 Source: National Vital Statistics System, multiple cause of death dataset, and DEA ARCOS Rate sales deaths treatment 1999 CDC. MMWR Year * 2007 opioid sales figure is preliminary. 139 Michigan is 10 th in the US: 140 WHY do doctors over prescribe? 107 prescriptions/100 people. The Four D s: Dated Dishonest Duped Disabled Pregnancy and Addiction 14

15 141 The Four D s: 142 The Four D s: Dishonest? Dated Disabled Duped Dishonest? Dated Disabled Duped 143 The Four D s: 144 The Four D s: Dishonest? Dated Disabled Duped Dishonest? Dated Disabled Duped Pressure on Doctors? 146 The Four D s: Dishonest Dated Disabled Duped The 5 th D: defamation Baker D. History of The Joint Commission s Pain Standards: Lessons for Today s Prescription Opioid Epidemic. JAMA, published online February 23, by 2004 this phrase was deleted from the accreditation standards manual. Lembke, Anna. Why Doctors Prescribe Opioids to known Opioid Abusers. n engl j med 367;17 nejm.org october 25, 2012 Pregnancy and Addiction 15

16 152 Naltrexone vs. Naloxone The Opioid Epidemic & Naloxone (Narcan ) Rescue Developed for Families Against Narcotics Naltrexone Oral (Rivea ) or IM (Vivitrol ) Slow onset Long acting (hours to weeks) Tightest binding to brain Used for PREVENTION of overdose (FDA) Naloxone IV, IM, SC or IN (Narcan, Evzio ) Rapid Onset Short acting (minutes) Less tightly bound Used for TREATMENT of overdose (FDA) Naloxone formulations: (0.4 mg) 154 Intranasal (I.N.): ADAPT (4mg/2mg!) Who is at Greatest Risk? 156 Fentanyl on Urine Drug Screen Pregnant Patient Abstinence > 2 weeks: treatment; jail; relapse. Discontinuing MAT: methadone; buprenorphine; Vivitrol (naltrexone). Mixing opioids with sedatives: alcohol, benzodiazepines, muscle relaxers FENTANYL 50% of UDS samples with heroin are pos for Fentanyl Pregnancy and Addiction 16

17 157 How To Do A Naloxone Rescue Naloxone in Pregnancy Make Sure They are Not Breathing (always) Call 911 Do Rescue Breaths (not compressions) Give Naloxone Resume Rescue Breaths Repeat Naloxone every 3 mins To review videos: go to ccmdphd on YouTube due to the risk of induced withdrawal, use of naloxone should be avoided during pregnancy and used only when absolutely necessary ASAM textbook of addiction medicine Naloxone in Pregnancy That statement is no longer operative. Ron Ziegler, President Nixon s Press Secretary Contact Information: Carl Christensen Office Cell: Website: Pregnancy and Addiction 17

Pregnancy, MAT and Addiction

Pregnancy, MAT and Addiction Pregnancy, MAT and Addiction Carl Christensen, MD, PhD, D-FASAM Clinical Associate Professor, OB Gyn & Psychiatry Wayne State University School of Medicine William Morrone, DO, MPH, DABAM Covenant Hospital

More information

Pregnancy and Addiction

Pregnancy and Addiction Pregnancy and Addiction Carl Christensen, MD, PhD, D-FASAM Clinical Associate Professor, OB Gyn & Psychiatry Wayne State University School of Medicine November 16, 2016 1 Educational Objectives At the

More information

Who is Behind the Opioid Epidemic?

Who is Behind the Opioid Epidemic? Safe and Effective Management of Pain and Addiction CARL CHRISTENSEN, MD PHD MEDICAL DIRECTOR, DAWN FARM CLINICAL ASSOCIATE PROFESSOR, WSU SCHOOL OF MEDICINE WWW.CHRISTENSENRECOVERY.COM Tonight s Talk:

More information

MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids

MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids MAT IN PREGNANCY R. COREY WALLER MD, MS PRINCIPAL, HEALTH MANAGEMENT ASSOCIATES FACULTY, INSTITUTE FOR HEALTHCARE INNOVATION (IHI) CHAIR, LEGISLATIVE ADVOCACY COMMITTEE, ASAM KAYLA LIFE STAGE 1: ADOLESCENCE

More information

Disclosures. Topics of today s training 4/24/2017. Evolving Treads in Medication Assisted Treatment. Christopher J Davis D.O.

Disclosures. Topics of today s training 4/24/2017. Evolving Treads in Medication Assisted Treatment. Christopher J Davis D.O. Evolving Treads in Medication Assisted Treatment Christopher J Davis D.O. CAADC, FASAM Medical Director, The Ranch of Pennsylvania Medical Director, Pyramid Healthcare Diplomate of The American Board of

More information

Does Treatment Work? Disclaimers. What is Addiction? Lack of Willpower? Addiction and Recovery News. Physiologic Dependence: Tolerance and Withdrawal

Does Treatment Work? Disclaimers. What is Addiction? Lack of Willpower? Addiction and Recovery News. Physiologic Dependence: Tolerance and Withdrawal Disclaimers Does Treatment Work? Carl Christensen MD PhD, FASAM Clinical Associate Professor, WSU School of Medicine Medical Director, Dawn Farm Medical Director, Mich Health Recovery Prof Program n n

More information

Does Treatment Work? Disclaimers. What is Recovery? Does Treatment Work? 5/16/17. To Get This PowerPoint and copies of the Articles.

Does Treatment Work? Disclaimers. What is Recovery? Does Treatment Work? 5/16/17. To Get This PowerPoint and copies of the Articles. Does Treatment Work? Carl Christensen MD PhD, FASAM Medical Director, Dawn Farm Clinical Associate Professor, WSU School of Medicine Medical Director, Mich Health Recovery Prof Program Advisory Board,

More information

Understanding and Combating the Heroin Epidemic

Understanding and Combating the Heroin Epidemic Understanding and Combating the Heroin Epidemic Kelly Dunn, Ph.D. Assistant Professor; Johns Hopkins School of Medicine Department of Psychiatry and Behavioral Sciences 1 Talk Outline What is causing the

More information

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Medication-Assisted Treatment. What Is It and Why Do We Use It? Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite

More information

Medication Assisted Treatment

Medication Assisted Treatment Meeting the Needs of Your Clients: Building Competencies in Mental Health and Addiction Services Medication Assisted Treatment November 5, 2018 In partnership with: House Keeping Because this is a webinar,

More information

Buprenorphine as a Treatment Option for Opioid Use Disorder

Buprenorphine as a Treatment Option for Opioid Use Disorder Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital

More information

Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone

Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone Alexander Y. Walley, MD, MSc Associate Professor of Medicine Director, Addiction Medicine Fellowship Boston University

More information

Identification and Treatment of Opioid Use Disorders in Primary Care Settings

Identification and Treatment of Opioid Use Disorders in Primary Care Settings Identification and Treatment of Opioid Use Disorders in Primary Care Settings 17th Annual Primary Care Symposium February 24, 2018 Kelly S. Barth, DO Associate Professor, Psychiatry & Internal Medicine

More information

Medication for the Treatment of Addiction (MAT)

Medication for the Treatment of Addiction (MAT) Medication for the Treatment of Addiction (MAT) Karol Kaltenbach, PhD Emeritus Professor of Pediatrics Sidney Kimmel Medical College at Thomas Jefferson University Terminology: Words Matter Medication

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

Pharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco

Pharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Pharmacotherapy for opioid addiction Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Disclosure slide No commercial conflicts to disclose. Gaps in current treatment of opioid

More information

Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP

Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP Overview Gavin Foundation Injectable naltrexone Community report

More information

Opioid dependence and buprenorphine treatment

Opioid dependence and buprenorphine treatment Opioid dependence and buprenorphine treatment David Roll, MD Revere Family Health, Cambridge Health Alliance Instructor in Medicine, Harvard Medical School Joji Suzuki MD Medical Director of Addictions

More information

Arwen Podesta, MD. ABIHM, ABAM, Forensic Psychiatry

Arwen Podesta, MD. ABIHM, ABAM, Forensic Psychiatry The State of Medicine in Addiction Recovery Arwen Podesta, MD ABIHM, ABAM, Forensic Psychiatry www.podestawellness.com 504-252-0026 http://www.addictionpolicy.org/ Overview Addiction is a serious, chronic

More information

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States

More information

Agenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model

Agenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model Agenda 1 Opioid Addiction in the United States 2 Evidence-based treatments for OUD OUD Treatment: Best Practices 4 Groups: Our Model 2 Groups is a national network of clinics providing affordable, evidencebased

More information

Anyone Can Become Addicted. Anyone.

Anyone Can Become Addicted. Anyone. Anyone Can Become Addicted. Anyone. PAStop.org Family Toolkit Seeking Drug Abuse Treatment: Know What to Ask Trying to identify the right treatment programs for a loved one can be a difficult process.

More information

Changing Course: statewide efforts to combat the opioid epidemic in California

Changing Course: statewide efforts to combat the opioid epidemic in California Changing Course: statewide efforts to combat the opioid epidemic in California Kelly Pfeifer, MD kpfeifer@chcf.org April 26, 2018 State of Reform conference STAT Special Report: 52 weeks, 52 faces Obituaries

More information

OPIOID SUBSTITUTION THERAPY RISKS & BENEFITS

OPIOID SUBSTITUTION THERAPY RISKS & BENEFITS OPIOID SUBSTITUTION THERAPY RISKS & BENEFITS LEO O. LANOIE, MD, MPH, FCFP, CCSAM, ABAM, FISAM, MRO Dr. Leo Lanoie, 2017 DISCLAIMER In the past year I have accepted funds from Purdue for speaking OPIOID

More information

Vivitrol Vs. Suboxone

Vivitrol Vs. Suboxone Vivitrol Vs. Suboxone Vivitrol - Naltrexone Indicated for opiate dependence and alcohol withdrawal pure antagonist 380mg once every 4 weeks IM Peak plasma concentration in 2 hrs, followed by a second peak

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder

6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder Rethinking Medication Treatment for Opioid Use Disorder International Conference on Opioids June 10, 2018 Dustin Patil, MD Fellow, Addiction Psychiatry Boston Medical Center John Renner, MD Professor of

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

Trends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville

Trends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville Trends and Challenges: The Kentucky Opioid Crisis Jason Smith, MD PhD University of Louisville Brief Introduction I am by no means an expert I have no financial disclosures Jokes are meant to be lighthearted

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice May 2013 Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Assistant Dean, Continuing Medical Education Case 32 yo female brought in after heroin overdose

More information

Opioid Use Disorders &Medication Treatment

Opioid Use Disorders &Medication Treatment Agency medical director comments Opioid Use Disorders &Medication Treatment Charissa Fotinos, MD, MSc Deputy Chief Medical Officer Washington State Health Care Authority Learning Objectives: 1) Review

More information

2/19/18. Today s talk. Today s talk. The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders

2/19/18. Today s talk. Today s talk. The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders Roger D. Weiss, MD Chief, Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA Professor of Psychiatry,

More information

Methadone and Naltrexone ER

Methadone and Naltrexone ER Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither I nor my

More information

THE OPIOID CRISIS 9/19/2018 DEFINING THE CRISIS DEFINING THE CRISIS NUMBER OF OPIOID-RELATED OVERDOSE DEATHS IN ALABAMA

THE OPIOID CRISIS 9/19/2018 DEFINING THE CRISIS DEFINING THE CRISIS NUMBER OF OPIOID-RELATED OVERDOSE DEATHS IN ALABAMA THE OPIOID CRISIS DEFINING THE CRISIS KATHLEEN DUPPER, MD MEDICAL DIRECTOR, HUNTSVILLE RECOVERY 19 th Annual Perinatal Conference: The Opioid Crisis September 21, 2018 DEFINING THE CRISIS NUMBER OF OPIOID-RELATED

More information

The role of behavioral interventions in buprenorphine treatment of opioid use disorders

The role of behavioral interventions in buprenorphine treatment of opioid use disorders The role of behavioral interventions in buprenorphine treatment of opioid use disorders Roger D. Weiss, MD Harvard Medical School, Boston, MA, McLean Hospital, Belmont, MA, USA Today s talk Review of studies

More information

Topics of today s training

Topics of today s training Extended Release Naltrexone Vivitrol Christopher J Davis D.O. CAADC, FASAM Medical Director, Brightwater Landing Medical Director, Pyramid Healthcare Diplomate of The American Board of Addition Medicine

More information

USE OF BUPRENORPHINE FOR CHRONIC PAIN

USE OF BUPRENORPHINE FOR CHRONIC PAIN Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences USE OF BUPRENORPHINE FOR CHRONIC PAIN MARK SULLIVAN, MD, PHD PSYCHIATRY AND BEHAVIORAL SCIENCES ANESTHESIOLOGY AND

More information

Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc.

Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc. Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc. Elements Behavioral Health Diplomate, American Board of Addiction

More information

Initiation of MAT for Opioid Use Disorder in the Hospitalized Patient and ER Setting: Promoting Best Outcomes in the Wake of an Opioid Crisis

Initiation of MAT for Opioid Use Disorder in the Hospitalized Patient and ER Setting: Promoting Best Outcomes in the Wake of an Opioid Crisis Initiation of MAT for Opioid Use Disorder in the Hospitalized Patient and ER Setting: Promoting Best Outcomes in the Wake of an Opioid Crisis Sponsored by the Florida Alcohol and Drug Abuse Association

More information

MAT in the Corrections Setting

MAT in the Corrections Setting MEDICATION ASSISTED TREATMENT AND CORRECTIONS Frank Filippelli, DO, PhD September 2017 MAT in the Corrections Setting Who Does This Affect? What is MAT and What is the Evidence of Efficacy? Emphasis on

More information

Noel Schenk MD. Davis Behavioral Health

Noel Schenk MD. Davis Behavioral Health Noel Schenk MD Davis Behavioral Health Michael Botticelli Director of National Drug Control Policy What is Addiction? Addiction is defined as a chronic, relapsing brain disease that is characterized by

More information

HARM REDUCTION & TREATMENT. Devin Reaves MSW

HARM REDUCTION & TREATMENT. Devin Reaves MSW HARM REDUCTION & TREATMENT Devin Reaves MSW The mission of PAHRC is to promote the health, dignity, and human rights of individuals who use drugs and communities impacted by drug use. Recognizing that

More information

MAT 101: TREATMENT OF OPIOID USE DISORDER

MAT 101: TREATMENT OF OPIOID USE DISORDER MAT 101: TREATMENT OF OPIOID USE DISORDER WITH SPECIAL EMPHASIS ON BUPRENORPHINE/NALOXONE ICADD May 22, 2018 Alicia Carrasco, MD Debby Woodall, LCSW, ACADC Magni Hamso, MD, MPH Terry Reilly Health Services

More information

Opiate Use Disorder and Opiate Overdose

Opiate Use Disorder and Opiate Overdose Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5

More information

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral

More information

Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC

Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC Objectives 1. Discuss the effects of opiate addiction on mothers and infants. 2. Discuss a Medical Home

More information

Medication-Assisted Treatment (MAT) Overview

Medication-Assisted Treatment (MAT) Overview Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for

More information

9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone)

9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone) 9/9/2016 Prior Authorization Form PASSPORT HEALTH PLAN KENTUCKY MEDICAID Buprenorphine Products This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

More information

SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program

SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers

More information

Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction

Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, M.D. Chief Medical Officer, Phoenix House Foundation Inc. Executive Director, Physicians for Responsible

More information

Opioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA

Opioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA Opioids October 29, 2010 Addiction Medicine Review Course CSAM, Newport Beach, CA Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Boston University School of Medicine Boston Medical

More information

Medication Assisted Treatment of Substance Use Disorders

Medication Assisted Treatment of Substance Use Disorders 3 rd Annual Challenges & Innovations in Rural Psychiatry Conference Medication Assisted Treatment of Substance Use Disorders June 22, 2016 Medication Assisted Treatment of Substance Use Disorders Richard

More information

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Medication Assisted Treatment MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Opioid Drugs Opium Morphine Heroin Codeine Oxycodone Roxycodone Oxycontin

More information

Discover the Hope: Opiate Treatment and Recovery

Discover the Hope: Opiate Treatment and Recovery Discover the Hope: Opiate Treatment and Recovery The Continued Struggle to Find and Implement Best Practices Ted Parran JR. M.D. FACP Carter and Isabel Wang Professor of Medical Education CWRU School of

More information

Buprenorphine pharmacology

Buprenorphine pharmacology Buprenorphine pharmacology Victorian Opioid Management ECHO Department of Addiction Medicine St Vincent s Hospital Melbourne 2018 Page 1 Opioids full, partial, antagonist Full Agonists - bind completely

More information

Substitution Therapy for Opioid Use Disorder The Role of Suboxone

Substitution Therapy for Opioid Use Disorder The Role of Suboxone Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM

More information

What is the strategy?

What is the strategy? What is the strategy? Multi-pronged approaches to reducing the health consequences of opioid use, New York City Northeast Epidemiology Conference Public health approach Track drug use and associated health

More information

Opioid Dependence During Pregnancy: Balancing Risk/Benefit

Opioid Dependence During Pregnancy: Balancing Risk/Benefit Opioid Dependence During Pregnancy: Balancing Risk/Benefit Peter R. Martin, M.D. Professor of Psychiatry and Pharmacology Vanderbilt University Acknowledgement: R01DA015713 Conflicts: None Outline I. Epidemiology

More information

Buprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17

Buprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Buprenorphine for Family Medicine Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Disclosures No conflicts of interest Off-label use of medications + Who here: Has taken care of a patient

More information

KRISANNA DEPPEN, MD FAMILY MEDICINE, ADDICTION MEDICINE GRANT MEDICAL CENTER-OHIOHEALTH COLUMBUS, OH

KRISANNA DEPPEN, MD FAMILY MEDICINE, ADDICTION MEDICINE GRANT MEDICAL CENTER-OHIOHEALTH COLUMBUS, OH KRISANNA DEPPEN, MD FAMILY MEDICINE, ADDICTION MEDICINE GRANT MEDICAL CENTER-OHIOHEALTH COLUMBUS, OH IF THESE MOMS REALLY CARED ABOUT THEIR BABIES, THEY WOULD JUST QUIT Those who can quit, often do Addiction

More information

GOALS AND OBJECTIVES

GOALS AND OBJECTIVES SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES

More information

Anesthetics, Local a / or Anesthesia, Epidural a / or Anesthesia, Obstetrical a / or Pain, Postoperative a / or Postpartum Period a

Anesthetics, Local a / or Anesthesia, Epidural a / or Anesthesia, Obstetrical a / or Pain, Postoperative a / or Postpartum Period a Appendix 1. Literature Search Databases Years Search Terms Pubmed 01/1966 1. Analgesics, Opioid a / or Opioid-related Disorders a / PsycINFO EMBASE Cochrane 09/2016 or Heroin a / or Heroin Dependence a

More information

Management of Opioid Use Disorder in Primary Care

Management of Opioid Use Disorder in Primary Care 1 Northwest ATTC presents Management of Opioid Use Disorder in Primary Care Joseph O. Merrill, MD, MPH University of Washington Associate Professor of Medicine 4/26/2018 Today s Presenter 2 Joseph Merrill,

More information

Methadone and Pregnancy

Methadone and Pregnancy Methadone and Pregnancy Methadone/Buprenorphine 101 Workshop, April 1, 2017 Charissa Patricelli, MD, CCFP, ABAM Clinical Associate Professor, Dept. of Family Practice UBC American Board of Addiction Medicine

More information

The Opioid Crisis: What Can Physicians Do About It?

The Opioid Crisis: What Can Physicians Do About It? The Opioid Crisis: What Can Physicians Do About It? Richard S. Schottenfeld, M.D. Professor and Chair, Department of Psychiatry and Behavioral Sciences 2018 Louis J. Kolodner Memorial Lecture Disclosures

More information

Latest Research on Addiction and Treatment

Latest Research on Addiction and Treatment Latest Research on Addiction and Treatment Joshua D Lee MD MSc joshua.lee@nyumc.org / @DrJoshuaDLee Associate Professor NYU School of Medicine, Department of Population Health Disclosures, LeeJD Grants:

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT/FIT 2016 April 2016 Daniel P. Alford, MD, MPH Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research and Education

More information

Medication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs

Medication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Medication Assisted Treatment Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Disclosures Employed by the Department of Veterans Affairs

More information

An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT

An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT Goals of Discussion Recognize opioid use disorder (OUD) Discuss the pharmacology of medication assisted treatments (MAT)

More information

Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction

Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, MD Co-Director, Opioid Policy Research Collaborative Heller School for Social Policy and Management Brandeis

More information

What Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016

What Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016 What Science Says about Opioid Use Disorder and Its Treatment Perilou Goddard, Ph.D. Department of Psychological Science Northern Kentucky University Examples of Opioids Agonists (activate opioid receptors)

More information

2/21/2018. What are Opioids?

2/21/2018. What are Opioids? Opioid Crisis: South Carolina Responds Carolyn Bogdon, MSN, FNP-BC Coordinator for Emergency Department Medication Assisted Treatment Program Medical University of South Carolina Opioid Crisis: A Mounting

More information

Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC

Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC Medications for Opioid Use Disorder Charles Brackett, MD, MPH General Internal Medicine, DHMC Opioid Related Deaths are on the Rise in the US National Vital Statistics System Mortality File Deaths are

More information

Responding to the Opioid Addiction Epidemic

Responding to the Opioid Addiction Epidemic Responding to the Opioid Addiction Epidemic Andrew Kolodny, M.D. Chief Medical Officer, Phoenix House Foundation Inc. Executive Director, Physicians for Responsible Opioid Prescribing Senior Scientist,

More information

MAT - ICAAD 2018 Ron Jackson, MSW, LICSW

MAT - ICAAD 2018 Ron Jackson, MSW, LICSW The ATTC Network Ten Regional Centers northwest@attcnetwork.org www.attcnetwork.org/northwest phone. 206-685-4419 1107 NE 45 th St, Ste 120, Seattle, WA 98105 http://attcnetwork.org/northwest U.S. Opioid

More information

Johann Hari. Truths 2/29/2016. From the street to the NICU. Treatment works

Johann Hari. Truths 2/29/2016. From the street to the NICU. Treatment works From the street to the NICU Richard Christensen, PA, CAS Johann Hari Treatment works Truths Disconnect with pregnant women seeking treatment Disconnect between community and science Medication is not a

More information

Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction

Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction The Problem The overdose death rate in Missouri and in the country has been rising for

More information

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008 Buprenorphine: An Introduction Sharon Stancliff, MD Harm Reduction Coalition September 2008 Objective Participants will be able to: Discuss the role of opioid maintenance in reducing morbidity and mortality

More information

Medication-assisted opioid addiction treatments: OB/GYN

Medication-assisted opioid addiction treatments: OB/GYN 5/13/16se Medication-assisted opioid addiction treatments: OB/GYN In October 2002, the Food and Drug Administration (FDA) approved buprenorphine monotherapy product, Subutex, and a buprenorphine/naloxone

More information

Vivitrol Drug Court and Medication Assisted Treatment

Vivitrol Drug Court and Medication Assisted Treatment Vivitrol Drug Court and Medication Assisted Treatment Amy Black, CNP and Judge Fred Moses Court program Self-starters Mission Statement To provide court-managed, medically assisted drug intervention treatment

More information

Treating Opioid Addiction

Treating Opioid Addiction Treating Opioid Addiction Some people who start taking opioid pain medications eventually have serious problems with them and become addicted. Every day, 68 people die in the US from opioid overdose. More

More information

Earl Hightower's Remarks 2014 National Rx Drug Abuse Summit Medication Assisted Treatment for Opiate Addiction

Earl Hightower's Remarks 2014 National Rx Drug Abuse Summit Medication Assisted Treatment for Opiate Addiction Earl Hightower's Remarks 2014 National Rx Drug Abuse Summit Medication Assisted Treatment for Opiate Addiction Thank you, Chairman Rogers, for holding this important Summit and helping to bring attention

More information

Maternal Substance Abuse: Challenges & Opportunities for Perinatal Nurses Catherine H. Ivory, PhD, RNC-OB October, 2015

Maternal Substance Abuse: Challenges & Opportunities for Perinatal Nurses Catherine H. Ivory, PhD, RNC-OB October, 2015 Maternal Substance Abuse: Challenges & Opportunities for Perinatal Nurses Catherine H. Ivory, PhD, RNC-OB October, 2015 Objectives Discuss the current scope of maternal substance use and abuse List examples

More information

Overdose Treatment. Naloxone is the drug of choice to treat methadone and other opioid overdose including heroin and morphine.

Overdose Treatment. Naloxone is the drug of choice to treat methadone and other opioid overdose including heroin and morphine. Part B 2 3 4 Overdose Treatment Naloxone is the drug of choice to treat methadone and other opioid overdose including heroin and morphine. Specifically used to counteract lifethreatening depression of

More information

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers

More information

Pennsylvania Coordinated Medication Assisted Treatment: A Penn State and Pennsylvania Psychiatric Institute Story

Pennsylvania Coordinated Medication Assisted Treatment: A Penn State and Pennsylvania Psychiatric Institute Story Pennsylvania Coordinated Medication Assisted Treatment: A Penn State and Pennsylvania Psychiatric Institute Story Sarah Sharfstein Kawasaki, MD Director of Addictions Services, Pennsylvania Psychiatric

More information

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine

More information

Disclosures. Objectives 2/5/2018. Women and opioid use disorder: Optimizing care during pregnancy and beyond

Disclosures. Objectives 2/5/2018. Women and opioid use disorder: Optimizing care during pregnancy and beyond Women and opioid use disorder: Optimizing care during pregnancy and beyond Susanne Astrab Fogger, DNP, PMHNP-BC, CARN-AP, FAANP Ashley L. Hodges, PhD, CRNP, WHNP-BC Disclosures Dr. Fogger has nothing to

More information

Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction

Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, M.D.. Executive Director, Physicians for Responsible Opioid Prescribing Senior Scientist, Heller School

More information

Addiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer

Addiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South

More information

Opioid Use Disorder Treatment Initiation in Diverse Settings

Opioid Use Disorder Treatment Initiation in Diverse Settings Opioid Use Disorder Treatment Initiation in Diverse Settings Sarah Wakeman, MD, FASAM Medical Director, Mass General Substance Use Disorder Initiative Assistant Professor, Harvard Medical School Disclosures

More information

Medication Assisted Treatment of an Opioid Use Disorder. J. Craig Allen, MD. Medical Director, Rushford

Medication Assisted Treatment of an Opioid Use Disorder. J. Craig Allen, MD. Medical Director, Rushford Medication Assisted Treatment of an Opioid Use Disorder J. Craig Allen, MD. Medical Director, Rushford Learning objectives At the conclusion of this activity, participants will be able to: Understand

More information

Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction

Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, MD Co-Director, Opioid Policy Research Collaborative Heller School for Social Policy and Management Brandeis

More information

Naloxone Statewide Standing Order. Cheryl A. Viracola, PharmD Pharmacy Programs Manager, Community Care of Wake and Johnston Counties

Naloxone Statewide Standing Order. Cheryl A. Viracola, PharmD Pharmacy Programs Manager, Community Care of Wake and Johnston Counties Naloxone Statewide Standing Order Cheryl A. Viracola, PharmD Pharmacy Programs Manager, Community Care of Wake and Johnston Counties Objectives Review the US & NC trends on opioid overdose Understand key

More information

Opioid Use Disorder- Pregnancy Principles and Myths. Brian Iriye MD and Farzad Kamyar MD High Risk Pregnancy Center

Opioid Use Disorder- Pregnancy Principles and Myths. Brian Iriye MD and Farzad Kamyar MD High Risk Pregnancy Center Opioid Use Disorder- Pregnancy Principles and Myths Brian Iriye MD and Farzad Kamyar MD High Risk Pregnancy Center History of NAS/NOWS Prior to 1875 infants not thought to be affected Congenital Morphinism

More information

Opioid Use Disorders as a Brain Disease Why MAT is so important. Ron Jackson, M.S.W., L.I.C.S.W.

Opioid Use Disorders as a Brain Disease Why MAT is so important. Ron Jackson, M.S.W., L.I.C.S.W. Opioid Use Disorders as a Brain Disease Why MAT is so important Ron Jackson, M.S.W., L.I.C.S.W. Affiliate Professor School of Social Work University of Washington Organization Name: CareOregon Course Title:

More information

Medication-Assisted Treatment (MAT) for Opioid Use Disorders

Medication-Assisted Treatment (MAT) for Opioid Use Disorders Medication-Assisted Treatment (MAT) for Opioid Use Disorders Sybil Marsh MA MD FASAM Department of Family Medicine and Community Health Case Western Reserve University/UHCMC Learning Objective 1 Following

More information

Suboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets

Suboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.32 Subject: Suboxone Drug Class Page: 1 of 7 Last Review Date: June 24, 2016 Suboxone Drug Class Description

More information

MAT for Opioid Dependence. MAT and Pain Management. Epidemiology. Epidemiology. Factors Impacting Pain Perception 9/23/2014

MAT for Opioid Dependence. MAT and Pain Management. Epidemiology. Epidemiology. Factors Impacting Pain Perception 9/23/2014 MAT for Opioid Dependence Methadone maintenance treatment (MMT) Buprenorphine/naloxone (suboxone) Buprenorhine/naloxone (BupNX) Buprenorphine SL Parenteral naltrexone (P-ntx) Oral naltrexone (ntx) MAT

More information

Medication Assisted Treatment as an alternative in Drug Courts*

Medication Assisted Treatment as an alternative in Drug Courts* Medication Assisted Treatment as an alternative in Drug Courts* National Drug Court Institute *portions of this presentation include adapted slides by Frances Levin, MD, Joshua Lee, MD, & Laurence Westreich,

More information